Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results

Autores
Van Deun, A.; Barrera, Lucía; Bastian, I.; Fattorini, L.; Hoffmann, H.; Kam, Kai Man; Rigouts, Leen; Ruesch-Gerdes, S.; Wright, A.
Año de publicación
2009
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains.
Fil: Van Deun, A. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.
Fil: Barrera, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio de Micobacterias; Argentina.
Fil: Bastian, I. Institute of Medical and Veterinary Science; Australia.
Fil: Fattorini, L. Istituto Superiore di Sanita; Italia.
Fil: Hoffmann, H. IML-Gauting; Alemania.
Fil: Kam, K. M. Centre for Health Protection; China.
Fil: Rigouts, L. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.
Fil: Ruesch-Gerdes, S. Forschungszentrum Borstel; Alemania.
Fil: Wright, A. World Health Organization; Suiza.
Fuente
Journal of Clinical Microbiology, 2009, 47(11), 3501–3506.
Materia
Mycobacterium tuberculosis
Rifampin
Nivel de accesibilidad
acceso abierto
Condiciones de uso
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:Publications/123456789/294

id SGCANLIS_72ccef3a90b04a29055741319abe1e9f
oai_identifier_str oai:sgc.anlis.gob.ar:Publications/123456789/294
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test ResultsVan Deun, A.Barrera, LucíaBastian, I.Fattorini, L.Hoffmann, H.Kam, Kai ManRigouts, LeenRuesch-Gerdes, S.Wright, A.Mycobacterium tuberculosisRifampinThe objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains.Fil: Van Deun, A. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.Fil: Barrera, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio de Micobacterias; Argentina.Fil: Bastian, I. Institute of Medical and Veterinary Science; Australia.Fil: Fattorini, L. Istituto Superiore di Sanita; Italia.Fil: Hoffmann, H. IML-Gauting; Alemania.Fil: Kam, K. M. Centre for Health Protection; China.Fil: Rigouts, L. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.Fil: Ruesch-Gerdes, S. Forschungszentrum Borstel; Alemania.Fil: Wright, A. World Health Organization; Suiza.2009info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf1098-660Xhttp://jcm.asm.org/content/47/11/3501.full.pdf+htmlhttp://sgc.anlis.gob.ar/handle/123456789/294Journal of Clinical Microbiology, 2009, 47(11), 3501–3506.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISenginfo:eu-repo/semantics/openAccess2025-09-04T11:15:39Zoai:sgc.anlis.gob.ar:Publications/123456789/294Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-04 11:15:39.647Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
title Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
spellingShingle Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
Van Deun, A.
Mycobacterium tuberculosis
Rifampin
title_short Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
title_full Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
title_fullStr Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
title_full_unstemmed Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
title_sort Mycobacterium tuberculosis Strains with Highly Discordant Rifampin Susceptibility Test Results
dc.creator.none.fl_str_mv Van Deun, A.
Barrera, Lucía
Bastian, I.
Fattorini, L.
Hoffmann, H.
Kam, Kai Man
Rigouts, Leen
Ruesch-Gerdes, S.
Wright, A.
author Van Deun, A.
author_facet Van Deun, A.
Barrera, Lucía
Bastian, I.
Fattorini, L.
Hoffmann, H.
Kam, Kai Man
Rigouts, Leen
Ruesch-Gerdes, S.
Wright, A.
author_role author
author2 Barrera, Lucía
Bastian, I.
Fattorini, L.
Hoffmann, H.
Kam, Kai Man
Rigouts, Leen
Ruesch-Gerdes, S.
Wright, A.
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Mycobacterium tuberculosis
Rifampin
topic Mycobacterium tuberculosis
Rifampin
dc.description.none.fl_txt_mv The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains.
Fil: Van Deun, A. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.
Fil: Barrera, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Servicio de Micobacterias; Argentina.
Fil: Bastian, I. Institute of Medical and Veterinary Science; Australia.
Fil: Fattorini, L. Istituto Superiore di Sanita; Italia.
Fil: Hoffmann, H. IML-Gauting; Alemania.
Fil: Kam, K. M. Centre for Health Protection; China.
Fil: Rigouts, L. Institute of Tropical Medicine. Mycobacteriology Unit; Bélgica.
Fil: Ruesch-Gerdes, S. Forschungszentrum Borstel; Alemania.
Fil: Wright, A. World Health Organization; Suiza.
description The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing. Nine Supra-National Tuberculosis Reference Laboratories tested the RMP susceptibilities of 19 selected M. tuberculosis strains, using standard culture-based methods. The strains were classified as definitely resistant (R) (n 6) or susceptible (S) (n 2) or probably resistant (PR) (n 8) or susceptible (PS) (n 3) based on rpoB mutations and treatment outcome. All methods yielded a susceptible result for the two S and three PS strains lacking an rpoB mutation and a resistant result for one R strain with a Ser531Leu mutation and one PR strain with a double mutation. Although the remaining 12 R and PR strains had rpoB mutations (four Asp516Tyr, three Leu511Pro, two Leu533Pro, one each His526Leu/Ser, and one Ile572Phe), they were all susceptible by the radiometric Bactec 460TB or Bactec 960 MGIT methods. In contrast, only one was susceptible by the proportion method on Lo¨wenstein-Jensen medium and two on Middlebrook 7H10 agar. Low-level but probably clinically relevant RMP resistance linked to specific rpoB mutations is easily missed by standard growth-based methods, particularly the automated broth-based systems. Further studies are required to confirm these findings, to determine the frequency of these low-level-resistant isolates, and to identify technical improvements that may identify such strains.
publishDate 2009
dc.date.none.fl_str_mv 2009
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 1098-660X
http://jcm.asm.org/content/47/11/3501.full.pdf+html
http://sgc.anlis.gob.ar/handle/123456789/294
identifier_str_mv 1098-660X
url http://jcm.asm.org/content/47/11/3501.full.pdf+html
http://sgc.anlis.gob.ar/handle/123456789/294
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv Journal of Clinical Microbiology, 2009, 47(11), 3501–3506.
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1842344418340765696
score 12.623145